To our knowledge, only the TNFα (−238) polymorphism has been described to be associated with improved survival in a study including MM patients treated with thalidomide [53] while there was only a trend towards an increased PFS in MM patients with the TNFα/LTα polymorphisms (−308, +252) treated with high dose chemotherapy [52]. The gene discussed is LTA; the disease is Miyoshi myopathy.